SEARCH

SEARCH BY CITATION

References

  • 1
    Tanis E, van de Velde CJ, Bartelink H et al. Locoregional recurrence after breast-conserving therapy remains an independent prognostic factor even after an event free interval of 10 years in early stage breast cancer. Eur J Cancer 2012; 48: 17516.
  • 2
    Truong PT, Lesperance M, Culhaci A et al. Patient subsets with T1–T2, node-negative breast cancer at high locoregional recurrence risk after mastectomy. Int J Radiat Oncol Biol Phys 2005; 62: 17582.
  • 3
    Albert JM, Gonzalez-Angulo AM, Guray M et al. Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer. Int J Radiat Oncol Biol Phys 2010; 77: 1296302.
  • 4
    Hasebe T, Imoto S, Yokose T et al. Histopathologic factors significantly associated with initial organ-specific metastasis by invasive ductal carcinoma of the breast: a prospective study. Hum Pathol 2008; 39: 68193.
  • 5
    Hasebe T, Iwasaki M, Akashi-Tanaka S et al. Important histologic outcome predictors for patients with invasive ductal carcinoma of the breast. Am J Surg Pathol 2011; 35: 148497.
  • 6
    Hasebe T, Iwasaki M, Akashi-Tanaka S et al. Atypical tumor-stromal fibroblasts in invasive ductal carcinoma of the breast. Am J Surg Pathol 2011; 35: 32536.
  • 7
    Hasebe T, Okada N, Iwasaki M et al. Grading system for lymph vessel tumor emboli: significant outcome predictor for invasive ductal carcinoma of the breast. Hum Pathol 2010; 41: 70615.
  • 8
    Hasebe T, Iwasaki M, Akashi-Tanaka S et al. Modified primary tumour/vessel tumour/nodal tumour classification for patients with invasive ductal carcinoma of the breast. Br J Cancer 2011; 105: 698708.
  • 9
    Hasebe T, Iwasaki M, Akashi-Tanaka S et al. Prognostic significance of mitotic figures in metastatic mammary ductal carcinoma to the lymph nodes. Hum Pathol 2011; 42: 182332.
  • 10
    Sobin LH, Gospodarowicz MK, Wittekind CH, eds. International Union Against Cancer TNM Classification of Malignant Tumours, 7th edn. Geneva: Wiley-Liss, 2009; 18193.
  • 11
    Hasebe T, Tsuda H, Hirohashi S et al. Fibrotic focus in invasive ductal carcinoma: an indicator of high tumor aggressiveness. Jpn J Cancer Res 1996; 87: 38594.
  • 12
    Hasebe T, Sasaki S, Imoto S et al. Prognostic significance of fibrotic focus in invasive ductal carcinoma of the breast: a prospective observational study. Mod Pathol 2002; 15: 50216.
  • 13
    Hasebe T, Okada N, Tamura N et al. p53 expression in tumor-stromal fibroblasts is closely associated with the outcome of patients with invasive ductal carcinoma. Cancer Sci 2009; 100: 21018.
  • 14
    Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131: 1843.
  • 15
    Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403l0.
  • 16
    Gilchrist KW, Gray R, Fowble B et al. Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive breast cancer: a 10-year follow-up study of 728 Eastern Cooperative Oncology Group patients. J Clin Oncol 1993; 11: 192935.
  • 17
    Hasebe T, Sasaki S, Imoto S et al. Characteristics of tumors in lymph vessels play an important role in the tumor progression of invasive ductal carcinoma of the breast: a prospective study. Mod Pathol 2001; 15: 90413.
  • 18
    Yamauchi C, Hasebe T, Iwasaki M et al. Accurate assessment of lymph vessel tumor emboli in invasive ductal carcinoma of the breast according to tumor areas, and their prognostic significance. Hum Pathol 2007; 38: 24759.
  • 19
    Abdulkarim BS, Cuartero J, Hanson J et al. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol 2011; 29: 28528.
  • 20
    Matsunuma R, Oguchi M, Fujikane T et al. Influence of lymphatic invasion on locoregional recurrence following mastectomy: indication for postmastectomy radiotherapy for breast cancer patients with one to three positive nodes. Int J Radiat Oncol Biol Phys 2012; 83: 84552.
  • 21
    Yang PS, Chen CM, Liu MC et al. Radiotherapy can decrease locoregional recurrence and increase survival in mastectomy patients with T1 to T2 breast cancer and one to three positive nodes with negative estrogen receptor and positive lymphovascular invasion status. Int J Radiat Oncol Biol Phys 2010; 77: 51622.
  • 22
    Hasebe T, Iwasaki M, Akashi-Tanaka S et al. Atypical tumor-stromal fibroblasts in invasive ductal carcinoma of the breast treated with neoadjuvant therapy. Hum Pathol 2011; 42: 9981006.
  • 23
    Kurose K, Gilley S, Matsumoto PH et al. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinoma. Nat Genet 2002; 32: 3557.
  • 24
    Patocs A, Zhang L, Xu Y et al. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med 2007; 357: 254351.
  • 25
    Hu B, Gharaee-Kermani M, Wu Z, Phan SH. Epigenetic regulation of myofibroblast differentiation by DNA methylation. Am J Pathol 2010; 177: 218.
  • 26
    Vered M, Dobriyan A, Dayan D et al. Tumor-host histopathologic variables, stromal myofibroblasts and risk score, are significantly associated with recurrent disease in tongue cancer. Cancer Sci 2009; 101: 27480.
  • 27
    Fiank G, Bertos N, Pepin F et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008; 14: 51827.
  • 28
    Singer CF, Gschwantler-Kaulich D, Fink-Retter A et al. Differential gene expression profile in breast cancer-derived stromal fibroblasts. Breast Cancer Res Treat 2008; 110: 27381.